EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data

Sofia Cividini iD, Ian Sinha iD, Giovanna Culeddu iD, Sarah Donegan iD, Michelle Maden iD, Katie Rose iD, Olivia Fulton iD, Dyfrig Hughes iD, Stephen Turner iD, Catrin Tudur Smith iD, EINSTEIN collaborative group

Health Technology Assessment · 2025

DOI: 10.3310/hgwt3617 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Health Technology Assessment, 2025. Verfasst von Sofia Cividini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Data Science (HDS), University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Anti-Asthmatic Agents, Asthma. Die Arbeit nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is no clear preferential option for initial step-up of treatment for children with uncontrolled asthma on inhaled corticosteroid.

Objectives

Evaluate the clinical effectiveness of pharmacological treatments to use in children with uncontrolled asthma on inhaled corticosteroid; identify and evaluate the potential for treatment effect modification to optimise treatment delivery; assess the cost-effectiveness of treatments.

Methods

Systematic review and individual participant data network meta-analysis. Studies were eligible if they were parallel or crossover randomised controlled trials comparing at least one of the pharmacological treatments of interest in participants aged < 18 years with uncontrolled asthma on any dose inhaled corticosteroid alone. We searched MEDLINE ® , Cochrane Library, Cochrane Central Register of Controlled Trials, EMBASE, National Institute for Health and Care Excellence Technology Appraisals, and the National Institute for Health and Care Research Health Technology Assessment series. Primary outcomes: exacerbation and asthma control. Secondary outcomes: health-related quality of life, mortality, forced expiratory volume in 1 second, adverse events, hospital admissions, symptoms (not analysed). We assessed the Risk Of Bias using the Cochrane Risk Of Bias tool and carried out Bayesian meta-analyses, network meta-analysis and network meta-regression, including treatment by covariate (age, sex, ethnicity, eczema, eosinophilia, asthma severity) interactions. A Markov decision-analytic model with a 12-month time horizon, which adopted the perspective of the National Health Service and Personal Social Services in the United Kingdom, was developed to compare alternative treatments. Cost-effectiveness was based on incremental costs per quality-adjusted life-years gained, with uncertainty considered in one-way, structural and probabilistic sensitivity analyses.

Results

We identified and screened 4708 publications from the search and confirmed 144 randomised controlled trials as eligible. We obtained individual participant data from 29 trials (5381 participants) and extracted limited aggregate data from a further 19 trials. The majority of trials had low risk of bias. The network meta-analysis suggests that medium-dose inhaled corticosteroid + long-acting β 2 -agonist is the preferred treatment for reducing odds of exacerbation [odds ratio 95% credibility interval: 0.43 (0.20 to 0.92) vs. low-dose inhaled corticosteroid; 40 studies, 8168 patients] and increasing forced expiratory volume in 1 second [mean difference 95% credibility interval: 0.71 (0.35 to 1.06) vs. low-dose inhaled corticosteroid; 23 studies, 2518 patients] while leukotriene receptor antagonist alone is the least preferred. No clear differences were found for asthma control (16 studies, 3027 patients). Limited pairwise analyses suggest some improvement in health-related quality of life for medium-dose inhaled corticosteroid versus inhaled corticosteroid + long-acting β 2 -agonist [two studies, paediatric asthma quality of life questionnaire, mean difference 95% credibility interval: 0.91 (0.29 to 1.53)]. The rate of hospitalisation due to an asthma attack ranged from 0.5% to 2.7% of patients across five trials. Slightly fewer patients reported neurological disorders (mild/moderate) on inhaled corticosteroid + long-acting β 2 -agonist versus inhaled corticosteroid + leukotriene receptor antagonist [odds ratio 95% confidence interval: 0.09 (0.01 to 0.82), one study]. There were no deaths recorded. We did not find convincing, consistent evidence to suggest that age, sex, ethnicity, eczema, eosinophilia, asthma severity would be regarded as an effect modifier. The economic analysis indicated that low-dose inhaled corticosteroid was the most cost-effective treatment option while medium-dose inhaled corticosteroid (alone and + long-acting β 2 -agonist) was associated with the highest number of quality-adjusted life-years, but their incremental cost-effectiveness exceeded the National Institute for Health and Care Excellence threshold.

Discussion

Medium-dose inhaled corticosteroid + long-acting β 2 -agonist is recommended for children with asthma that is uncontrolled on inhaled corticosteroid alone; leukotriene receptor antagonist alone should be avoided. We could not include data from 67% of the eligible trials, conclusions should therefore be viewed with some caution. Study registration This study is registered as PROSPERO CRD42019127599. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/110/16) and is published in full in Health Technology Assessment ; Vol. 29, No. 15. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex HormonesAnti-Asthmatic AgentsAsthmaAdolescentChildHumansAdministration, InhalationCost-Benefit AnalysisCost-Effectiveness AnalysisQuality of LifeQuality-Adjusted Life YearsRandomized Controlled Trials as TopicTechnology Assessment, Biomedical

Stichwörter der Autor:innen

ADOLESCENTSANTIASTHMATIC AGENTSASTHMAASTHMA ATTACKASTHMA CONTROLCHILDRENCOST-EFFECTIVENESS ANALYSISECONOMIC EVALUATIONEXACERBATIONINDIVIDUAL PARTICIPANT DATAINHALED CORTICOSTEROIDSIPDNETWORK META-ANALYSISNETWORK META-REGRESSIONNMA

Substanzen

Adrenal Cortex HormonesAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Health Data Science (HDS), University of Liverpool, Liverpool, UK.
  • Alder Hey Children's Foundation NHS Trust, Liverpool, UK.
  • Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor, UK.
  • Liverpool Reviews and Implementation Group (LRIG), University of Liverpool, Liverpool, UK.
  • Patient Representative, Liverpool, UK.
  • University Court of the University of Aberdeen, Aberdeen, UK.

ORCID-Profile: Sofia Cividini, Ian Sinha, Giovanna Culeddu, Sarah Donegan, Michelle Maden, Katie Rose, Olivia Fulton, Dyfrig Hughes, Stephen Turner, Catrin Tudur Smith

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Cividini, S., Sinha, I., Culeddu, G., Donegan, S., Maden, M., Rose, K., Fulton, O., Hughes, D., Turner, S., Smith, C. T., & EINSTEIN collaborative group (2025). Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data. Health Technology Assessment. https://doi.org/10.3310/hgwt3617

Vancouver

Cividini S, Sinha I, Culeddu G, Donegan S, Maden M, Rose K, et al. Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data. Health Technology Assessment. 2025. doi:10.3310/hgwt3617

BibTeX
@article{Cividini2025,
  author = {Cividini, Sofia and Sinha, Ian and Culeddu, Giovanna and Donegan, Sarah and Maden, Michelle and Rose, Katie and Fulton, Olivia and Hughes, Dyfrig and Turner, Stephen and Smith, Catrin Tudur and EINSTEIN collaborative group, EINSTEIN collaborative group},
  title = {Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data},
  journal = {Health Technology Assessment},
  year = {2025},
  doi = {10.3310/hgwt3617}
}
Kostenlos starten →